Articles
Before your retina surgery, make sure you’re fully informed. Discover the top 3 questions to ask your retina eye specialist to ensure safe, confident, and successful treatment.
Facing any kind of surgery can feel overwhelming, especially when it involves your vision. If you are scheduled for a procedure on your retina, having a clear and open conversation with your retina eye specialist is the first step toward feeling more confident and prepared. This discussion helps you understand the process, manage your expectations, and play an active role in your own care. Knowing what to ask can make all the difference. To help you prepare, we’ve put together three essential questions to bring to your next appointment. These questions will cover the details of the procedure, what to expect during re…
Facing any kind of surgery can feel overwhelming, especially when it involves your vision. If you are scheduled for a procedure on your retina, having a clear and open conversation with your retina eye specialist is the first step toward feeling more confident and prepared. This discussion helps you understand the process, manage your expectations, and play an active role in your own care. Knowing what to ask can make all the difference. To help you prepare, we’ve put together three essential questions to bring to your next appointment. These questions will cover the details of the procedure, what to expect during re…
Learn why healthspan, the years lived in good health, matters more than lifespan. See how genetics, lifestyle, and Noorns insights can help you live better, not just longer.
Healthspan—the years we live in good health—matters more than lifespan alone. While medical advances have extended how long we live, most people now spend a decade or more in poor health at the end of life. The real challenge of longevity is not just adding years, but ensuring those years remain active, independent, and fulfilling. This article explores the growing focus on healthspan through five proven pillars: movement, nutrition, sleep and stress management, social connection, and preventive care. It also examines how genetics and DNA methylation influence the pace of aging—and how lifestyle choices can modify those…
Healthspan—the years we live in good health—matters more than lifespan alone. While medical advances have extended how long we live, most people now spend a decade or more in poor health at the end of life. The real challenge of longevity is not just adding years, but ensuring those years remain active, independent, and fulfilling. This article explores the growing focus on healthspan through five proven pillars: movement, nutrition, sleep and stress management, social connection, and preventive care. It also examines how genetics and DNA methylation influence the pace of aging—and how lifestyle choices can modify those…
07-Oct-2025
Regenerative Macrophage Therapy uses patient-derived or engineered macrophages to heal tissue damage, reduce fibrosis, and regenerate function. In the liver, early trials (e.g. MATCH, EMERALD/RTX001) have shown safety and potential reductions in complications. Challenges remain around manufacturing, phenotype stability, and broadening into other organs.
Regenerative Macrophage Therapy is an emerging cell-based treatment approach that leverages specially programmed or engineered macrophages to promote tissue repair, reduce inflammation, and reverse fibrosis in damaged organs. Rather than suppressing the immune response, it aims to direct the body’s innate immune machinery toward regeneration and healing. What are macrophages and why they matter Macrophages are innate immune cells that patrol…
Regenerative Macrophage Therapy is an emerging cell-based treatment approach that leverages specially programmed or engineered macrophages to promote tissue repair, reduce inflammation, and reverse fibrosis in damaged organs. Rather than suppressing the immune response, it aims to direct the body’s innate immune machinery toward regeneration and healing. What are macrophages and why they matter Macrophages are innate immune cells that patrol…
In longitudinal clinical trials, missing data is a threat to scientific integrity. Whether due to patient dropouts, missed visits, or protocol deviations, these gaps can distort results, reduce statistical power, and invite regulatory scrutiny. With dropout rates averaging around 3-8% for the last three years, the stakes are high. As the industry continues to evolve, so should the strategies we implement.
In longitudinal clinical trials, missing data is a threat to scientific integrity. Whether due to patient dropouts, missed visits, or protocol deviations, these gaps can distort results, reduce statistical power, and invite regulatory scrutiny. With dropout rates averaging around 3-8% for the last three years, the stakes are high. As the industry continues to evolve, so should the str…
In longitudinal clinical trials, missing data is a threat to scientific integrity. Whether due to patient dropouts, missed visits, or protocol deviations, these gaps can distort results, reduce statistical power, and invite regulatory scrutiny. With dropout rates averaging around 3-8% for the last three years, the stakes are high. As the industry continues to evolve, so should the str…
The global ringworm treatment market was valued at USD 15.5 billion in 2024 and is projected to grow from USD 16 billion in 2025 to USD 25 billion by 2034, at a CAGR of 5.1%. Growth is driven by the rising prevalence of ringworm infections, easy access to over-the-counter antifungal drugs, and increased awareness about symptoms and treatment.
The global ringworm treatment market is set for steady growth over the coming decade, driven by increasing infection rates, improved awareness, and broad access to antifungal medications. Valued at USD 15.5 billion in 2024, the market is projected to expand from USD 16 billion in 2025 to USD 25 billion by 2034, reflecting a compound annual growth rate (CAGR) of 5.1% during the forecast period. One of the primary drivers of this growth is the rising pre…
The global ringworm treatment market is set for steady growth over the coming decade, driven by increasing infection rates, improved awareness, and broad access to antifungal medications. Valued at USD 15.5 billion in 2024, the market is projected to expand from USD 16 billion in 2025 to USD 25 billion by 2034, reflecting a compound annual growth rate (CAGR) of 5.1% during the forecast period. One of the primary drivers of this growth is the rising pre…
The Powered Surgical Instrument Market is witnessing steady growth, driven by rising surgical volumes, an aging global population, and rapid technological advancements. Valued at USD 2.65 billion in 2024, the market is projected to reach USD 3.71 billion by 2033, expanding at a CAGR of 3.9%. Key growth factors include the adoption of minimally invasive procedures, demand for precision in orthopedic and reconstructive surgeries, and the integration of battery-powered and ergonomic devices. North America currently dominates the Powered Surgical Instrument Market Share, while Asia-Pacific is poised for the fastest growth. Challenges such as high costs, sterilization risks, and training gaps persist, but innovations like robotic integration and cordless systems are shaping future opportunities.
SecureFlex will be commercially available in Europe and Japan in Autumn 2025, with a subsequent global rollout subject to regulatory requirements such as product registration and market clearance.
TOKYO & HAMBURG, Oct 6, 2025 - (JCN Newswire) - Olympus Corporation (Olympus), a global MedTech company committed to making people’s lives healthier, safer and more fulfilling, today announced the launch of SecureFlex, a single-use fine needle biopsy device. SecureFlex will be commercially available in Europe and Japan in Autumn 2025, with a subsequent global rollout subject to regulatory requirements such as product registration and market clearance. Designed for use with an ultrasound endoscope, SecureFlex supports endoscopic ultrasound-guided fine needle b…
TOKYO & HAMBURG, Oct 6, 2025 - (JCN Newswire) - Olympus Corporation (Olympus), a global MedTech company committed to making people’s lives healthier, safer and more fulfilling, today announced the launch of SecureFlex, a single-use fine needle biopsy device. SecureFlex will be commercially available in Europe and Japan in Autumn 2025, with a subsequent global rollout subject to regulatory requirements such as product registration and market clearance. Designed for use with an ultrasound endoscope, SecureFlex supports endoscopic ultrasound-guided fine needle b…
Workforce development and training in the pharmaceutical industry — a great fit for PharmiWeb readers
In an era where technological innovation is transforming the pharmaceutical and life sciences industry, the importance of workforce development has never been greater. As new drug discovery methods, advanced manufacturing technologies, and digital health solutions emerge, companies face increasing pressure to equip their teams with the skills needed to stay competitive. Bridging the Skill Gap in a Changing Industry The pharmaceutical sector is undergoing a rapid evolution, driven by automation, data analytics, and AI-based research. While these advances bring new opportunities, they also create skill gaps that can slow innovation and reduce productivity. Investing in workforce development p…
In an era where technological innovation is transforming the pharmaceutical and life sciences industry, the importance of workforce development has never been greater. As new drug discovery methods, advanced manufacturing technologies, and digital health solutions emerge, companies face increasing pressure to equip their teams with the skills needed to stay competitive. Bridging the Skill Gap in a Changing Industry The pharmaceutical sector is undergoing a rapid evolution, driven by automation, data analytics, and AI-based research. While these advances bring new opportunities, they also create skill gaps that can slow innovation and reduce productivity. Investing in workforce development p…
A new study has revealed how NHS waiting lists are pushing patients into risky choices - with some delaying or even avoiding care altogether, despite potential cancer symptoms.
A new study has revealed how NHS waiting lists are pushing patients into risky choices - with some delaying or even avoiding care altogether, despite potential cancer symptoms. The survey of 2,000 adults found nearly a third (29%) have put off seeking care due to long waits, while more than one in five (22%) admit they have avoided seeking care altogether. Alarmingly, one in five (20%) delayed seeing a doctor even after noticing possible cancer symptoms. Doctors warn this behaviour could mean hundreds of cancers are going undiagnosed, or being caught later when survival chances are reduced. NHS data shows that more t…
A new study has revealed how NHS waiting lists are pushing patients into risky choices - with some delaying or even avoiding care altogether, despite potential cancer symptoms. The survey of 2,000 adults found nearly a third (29%) have put off seeking care due to long waits, while more than one in five (22%) admit they have avoided seeking care altogether. Alarmingly, one in five (20%) delayed seeing a doctor even after noticing possible cancer symptoms. Doctors warn this behaviour could mean hundreds of cancers are going undiagnosed, or being caught later when survival chances are reduced. NHS data shows that more t…
The most successful drug launches in 2025 will combine market analysis, regulatory planning, payer engagement, strong branding, and real world evidence. Patient centric strategies and teamwork remain the foundation of commercial success.
Bringing a new therapy to market is one of the most complex challenges in the pharmaceutical industry. Success depends on more than regulatory approval. It requires a coordinated strategy that engages stakeholders, demonstrates value, and reaches patients effectively. Below are seven key steps that define a successful drug launch strategy in 2025. 1. Conduct Comprehensive Market Analysis Understanding unmet medical needs, patient populations, and competitor activity is essential. Early market research ensures that your therapy is positioned with a clear val…
Bringing a new therapy to market is one of the most complex challenges in the pharmaceutical industry. Success depends on more than regulatory approval. It requires a coordinated strategy that engages stakeholders, demonstrates value, and reaches patients effectively. Below are seven key steps that define a successful drug launch strategy in 2025. 1. Conduct Comprehensive Market Analysis Understanding unmet medical needs, patient populations, and competitor activity is essential. Early market research ensures that your therapy is positioned with a clear val…
The Bachem team share their insights on the evolving relationship between pharma companies and CDMOs
Outsourcing plays a critical role in modern drug development and manufacturing – one which has gained increasing importance in recent years. The continued rise in demand for complex modalities, such as peptides and oligonucleotides, and increased pressures on time-to-market, have amplified the need for external partnerships and collaboration to ensure supply of crucial medication to patients. As a result, pharmaceutical outsourcing is moving away from transactional, fee-for-service arrangements, toward long-term, strategic partnerships. With a greater need to ensure delivery of medication to patients, industry players are promoting enhanced collaboration, through acknowledging shared goals a…
Outsourcing plays a critical role in modern drug development and manufacturing – one which has gained increasing importance in recent years. The continued rise in demand for complex modalities, such as peptides and oligonucleotides, and increased pressures on time-to-market, have amplified the need for external partnerships and collaboration to ensure supply of crucial medication to patients. As a result, pharmaceutical outsourcing is moving away from transactional, fee-for-service arrangements, toward long-term, strategic partnerships. With a greater need to ensure delivery of medication to patients, industry players are promoting enhanced collaboration, through acknowledging shared goals a…
Biocomputing, the use of biological molecules or cells to process data, is currently in the lab stage but rapidly progressing. Early adoption in pharma and biotech could begin in the late 2020s, with broader mainstream applications likely in the 2030s.
Biocomputing sits at the frontier of technological innovation, using biological molecules, cells or tissues to carry out computational tasks rather than relying solely on silicon circuits. As a hybrid between life sciences and information science, it promises energy efficiency, massive parallelism and deeper integration with living systems. Current Status: Early Breakthroughs and Demonstrators Today biocomputing is still in its infancy, existing mainly in research labs, pilot systems and proof-of-concept devices. Advances range from neuron-ba…
Biocomputing sits at the frontier of technological innovation, using biological molecules, cells or tissues to carry out computational tasks rather than relying solely on silicon circuits. As a hybrid between life sciences and information science, it promises energy efficiency, massive parallelism and deeper integration with living systems. Current Status: Early Breakthroughs and Demonstrators Today biocomputing is still in its infancy, existing mainly in research labs, pilot systems and proof-of-concept devices. Advances range from neuron-ba…
Leading pharma companies make faster decisions through advanced data visualisation, gaining competitive advantages in clinical trials, regulatory approvals, and operations. The gap between visualisation-mature organisations and those using static reports is widening, creating a strategic imperative for investment.
In the high-stakes world of pharmaceutical development, the difference between industry leaders and laggards often comes down to a single factor: decision velocity. The organisations that consistently win aren't necessarily those with the most data - they're the ones who can transform that data into decisions faster than their competitors. The Cost of the Visualisation Gap Consider two pharmaceutical companies running parallel Phase III trials. Company A relies on traditional mont…
In the high-stakes world of pharmaceutical development, the difference between industry leaders and laggards often comes down to a single factor: decision velocity. The organisations that consistently win aren't necessarily those with the most data - they're the ones who can transform that data into decisions faster than their competitors. The Cost of the Visualisation Gap Consider two pharmaceutical companies running parallel Phase III trials. Company A relies on traditional mont…
By establishing a safe and impenetrable record of each charge, payment or adjustment blockchain technology has the potential to increase medical billing transparency. Patients, providers and insurers can all view the shared ledger in real time, reducing billing errors, fraud and hidden costs while also making the process easier to track and comprehend by enhancing clarity and trust, blockchain technology could make medical billing easier and more equitable for all parties.
Introduction: Unmasking the Medical Billing Maze If you have ever felt lost trying to decipher a hospital bill or an insurance Explanation of Benefits (EOB) you are not alone the journey from receiving a medical service to paying the final bill is convoluted, often involving multiple intermediaries, archaic data systems a…
Introduction: Unmasking the Medical Billing Maze If you have ever felt lost trying to decipher a hospital bill or an insurance Explanation of Benefits (EOB) you are not alone the journey from receiving a medical service to paying the final bill is convoluted, often involving multiple intermediaries, archaic data systems a…
In the pharmaceutical industry, drug packaging is the last critical line of defense for ensuring product quality and patient safety. Faced with increasingly stringent regulatory compliance, cross-contamination, and production efficiency challenges, traditional packaging equipment is no longer sufficient. This article explores the core pain points of modern pharmaceutical packaging and explains why superior packaging machinery must be a stable, intelligent, and verifiable turnkey solution to truly serve as the "invisible guardian" of drug quality. Discover how to build this final barrier for your product.
In the pharmaceutical industry, every pill and every dose carries the weight of life. While we often focus on the R&D and synthesis of active ingredients, we often overlook the f…
In the pharmaceutical industry, every pill and every dose carries the weight of life. While we often focus on the R&D and synthesis of active ingredients, we often overlook the f…
In 2025, clinics and hospitals are rapidly adopting digital tools to improve efficiency and patient care. Healcard stands out as a complete clinic management solution offering electronic health records, smart billing, mobile access, and secure data management. Streamlining daily operations helps doctors save time, reduce errors, and focus more on patients. Healcard isn’t just software; it’s a step toward smarter, more connected healthcare.
Introduction Healthcare’s changing fast. Old-school ways, paper files, long waits, manual billing, they just don’t cut it anymore. Clinics and hospitals now need software that works for them, not against them. It’s 2025, and to deliver good care, you need efficiency, speed, and accuracy. That’s where Healcard steps in. Designed for Indian clinics and hosp…
Introduction Healthcare’s changing fast. Old-school ways, paper files, long waits, manual billing, they just don’t cut it anymore. Clinics and hospitals now need software that works for them, not against them. It’s 2025, and to deliver good care, you need efficiency, speed, and accuracy. That’s where Healcard steps in. Designed for Indian clinics and hosp…
The global Penicillin Active Pharmaceutical Ingredients (API) market was valued at USD 2.95 billion in 2023 and is projected to reach USD 4.79 billion by 2032, growing at a CAGR of 5.6%. This growth is driven by the increasing demand for antibiotics, advancements in manufacturing technologies, and the expansion of healthcare infrastructure in emerging economies. The report provides an in-depth analysis of market trends, key players, and regional dynamics, offering valuable insights for stakeholders in the pharmaceutical industry.
The Penicillin Active Pharmaceutical Ingredients (APIs) market represents a cornerstone of the global pharmaceutical industry, providing the essential building blocks for antibiotics that combat a wide range of bacterial infections. With its critical role in health…
The Penicillin Active Pharmaceutical Ingredients (APIs) market represents a cornerstone of the global pharmaceutical industry, providing the essential building blocks for antibiotics that combat a wide range of bacterial infections. With its critical role in health…
Clinical trials are the backbone of modern medicine but they have historically suffered from a lack of diversity among their participants this has created significant gaps in our understanding of how treatments and medications affect different groups of people this article explores the critical need for diversity in clinical trial recruitment discussing the scientific and ethical reasons behind it, the barriers that prevent it and the strategies being implemented to create a more inclusive and effective future for medical research by ensuring trials are representative of the global population we can improve the safety and efficacy of new therapies for everyone, build greater public trust and move closer to achieving true health equity.
Introduction In the world of medical breakthroughs, cli…
Introduction In the world of medical breakthroughs, cli…
29-Sep-2025
As cannabis research continues to progress, increasing attention is being given to two promising compounds, cannabigerol (CBG) and its precursor, cannabigerolic acid (CBG-A). Often overshadowed by the more widely recognised cannabinoids THC and CBD, these non-psychoactive compounds are now being explored for their therapeutic potential.
As cannabis research continues to progress, increasing attention is being given to two promising compounds, cannabigerol (CBG) and its precursor, cannabigerolic acid (CBG-A). Often overshadowed by the more widely recognised cannabinoids THC and CBD, these non-psychoactive compounds are now being explored for their therapeutic potential. Broughton, a leading UK-based contract research organisation, explores early research on the potential of these cannabinoid…
As cannabis research continues to progress, increasing attention is being given to two promising compounds, cannabigerol (CBG) and its precursor, cannabigerolic acid (CBG-A). Often overshadowed by the more widely recognised cannabinoids THC and CBD, these non-psychoactive compounds are now being explored for their therapeutic potential. Broughton, a leading UK-based contract research organisation, explores early research on the potential of these cannabinoid…
The global Ambulatory EHR Market is projected to grow from USD 6.1 billion in 2023 to USD 10.5 billion by 2032 at a CAGR of 6.3%. Explore market size, major regional trends, deployment shifts toward cloud/web-based models, leading vendors, and what to expect through 2032 in this comprehensive analysis guided by Ameco Research.
In recent years, the healthcare industry has undergone rapid digital transformation. Among its key components is the adoption of Ambulatory EHR (Electronic Health Records in outpatient / ambulatory care settings) systems. These solutions are essential tools for physician offices, specialty clinics, and other outpatient facilities to maintain accurate patient histories, manage clinical workflows, enable remote care protocols, and meet regulatory requirements. As pressu…
In recent years, the healthcare industry has undergone rapid digital transformation. Among its key components is the adoption of Ambulatory EHR (Electronic Health Records in outpatient / ambulatory care settings) systems. These solutions are essential tools for physician offices, specialty clinics, and other outpatient facilities to maintain accurate patient histories, manage clinical workflows, enable remote care protocols, and meet regulatory requirements. As pressu…
